https://www.selleckchem.com/pr....oducts/guanosine-5-t
8 11.1%, .01) in UC and non-structuring, non-penetrating behavior in CD (90.0 44.4%, = .03); however, this was not confirmed in multivariate analysis. Discontinuation due to primary non-response occurred in 20.0 and 5.3% of UC and CD patients, respectively, while rates of secondary loss of response were 12.0 and 5.3% after 52 weeks of follow-up. Vedolizumab was well-tolerated as only one UC patient experienced a serious adverse event. Vedolizumab is effective in the achievement of short-term, long-term,
Like
Comment
Share
